07:19 AM EST, 12/11/2024 (MT Newswires) -- MannKind ( MNKD ) and its Indian partner Cipla said Wednesday that India's Central Drugs Standard Control Organization has approved Afrezza inhalation powder for adults with diabetes.

MannKind ( MNKD ) expects to ship Afrezza to Cipla by the end of 2025, the companies said.

Under an exclusive marketing and distribution agreement for Afrezza, Cipla was responsible for obtaining regulatory approvals as well as marketing and sales of Afrezza in India, while MannKind ( MNKD ) supplies the product to Cipla, according to a joint statement.

Afrezza is approved in the US and Brazil, the companies added.